- Title
- Comorbidities Modify the Phenotype but Not the Treatment Effectiveness to Mepolizumab in Severe Eosinophilic Asthma
- Creator
- Kritikos, Vicky; Harvey, Erin S.; Thomas, Dennis; Gibson, Peter G.; Australian Mepolizumab Registry Investigators,; Stevens, Sean; Katelaris, Constance H.; Langton, David; Rimmer, Janet; Farah, Claude S.; Gillman, Andrew; Hew, Mark; Radhakrishna, Naghmeh
- Relation
- Journal of Allergy and Clinical Immunology: In Practice Vol. 11, Issue 3, p. 885-895.e13
- Publisher Link
- http://dx.doi.org/10.1016/j.jaip.2022.12.004
- Publisher
- Elsevier
- Resource Type
- journal article
- Date
- 2023
- Description
- Background: Comorbidities in severe asthma are common and contribute to disease burden. The severe asthma phenotype and treatment response can be impacted by comorbid conditions. Real-world data on the use of mepolizumab in severe eosinophilic asthma (SEA) in the presence of comorbidities are needed to inform clinical practice. Objective: To investigate the impact of comorbid conditions on baseline phenotype in patients with SEA and assess the mepolizumab treatment effect by comorbidity status in SEA. Methods: Patients enrolled in the Australian Mepolizumab Registry (n = 309) were classified into subgroups defined by the presence or absence of comorbidities, including nasal polyps, aspirin-exacerbated airway disease, asthma-chronic obstructive pulmonary disease overlap (ACO), fungal sensitization, and obesity. Patient baseline characteristics were compared, and the impacts of comorbidity on phenotype, identified by differences in patient age and/or baseline biomarker levels and/or asthma severity, were assessed. The mepolizumab treatment effects on clinical and biological outcomes at 12 months were assessed. Results: Across comorbidity subgroups, mepolizumab reduced the rate of clinically significant exacerbations (range: 47%-77%), maintenance oral corticosteroid use (dose reduction: 4.2-13.3 mg/d), and improved symptom control (Asthma Control Questionnaire-5 score: 1.9-2.4 point reduction) and lung function (mean: 3.4-9.3 post-bronchodilator percent predicted forced expiratory volume in 1 second). Peripheral blood eosinophils were reduced (mean: 480-780 cells/μL). Comorbidities (nasal polyps, obesity, ACO, and fungal sensitization) modified the baseline phenotype. Conclusions: Mepolizumab treatment is associated with comparable clinical improvements in patients with SEA and comorbidities. Mepolizumab effectively minimizes the disease impact and corticosteroid burden in patients with SEA.
- Subject
- mepolizumab; severe eosinophilic asthma; eosinophilic inflammation; comorbidity; phenotype; SDG 3; Sustainable Development Goals
- Identifier
- http://hdl.handle.net/1959.13/1477453
- Identifier
- uon:49984
- Identifier
- ISSN:2213-2198
- Language
- eng
- Reviewed
- Hits: 2105
- Visitors: 2100
- Downloads: 0
Collections
Goal 3: Good Health and Well-Being
| Thumbnail | File | Description | Size | Format |
|---|